Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis

Regulation of Adaptive Immunity by the Fractalkine Receptor during Autoimmune Inflammation

(2013) J. A. Garcia et al.   JOURNAL OF IMMUNOLOGY

Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX3CR1)

(2013) Sofia Karlström et al.   JOURNAL OF MEDICINAL CHEMISTRY

Natalizumab

(2012) Richard Rudick et al.   JAMA Neurology

Treatment of multiple sclerosis: current concepts and future perspectives

(2011) Dorothea Buck et al.   JOURNAL OF NEUROLOGY

Progressive multifocal leukoencephalopathy and natalizumab

(2011) Kerstin Hellwig et al.   JOURNAL OF NEUROLOGY

EAE: imperfect but useful models of multiple sclerosis

(2011) Bert A. ’t Hart et al.   TRENDS IN MOLECULAR MEDICINE

The blood–brain barrier, chemokines and multiple sclerosis

(2010) David W. Holman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential

(2010) Jan G D'Haese et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Regulation of translocator protein 18kDa (TSPO) expression in health and disease states☆

(2010) Amani Batarseh et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Animal models of multiple sclerosis—Potentials and limitations

(2010) Eilhard Mix et al.   PROGRESS IN NEUROBIOLOGY

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

(2009) Dimitrios Papadopoulos et al.   JOURNAL OF NEUROSCIENCE RESEARCH

The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity

(2008) Monika Pruenster et al.   NATURE IMMUNOLOGY